ICP-490 vs Mezigdomide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline
ICP-490
Developed by Beijing InnoCare Pharma Tech Co.
NCT05719701 · Phase 1/2 · status unknown
This is an unblinded, non-randomized dose-finding study with no control arm, and no results have been posted yet, so it cannot currently demonstrate a controlled treatment effect.
No aligned efficacy figure on record for this race.
Mezigdomide
Developed by Bristol-Myers Squibb
NCT05552976 · Phase 3 · active, not recruiting
This was a randomized, open-label Phase 3 trial with 606 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-03-09. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate.
Next expected readout: November 2026 · NCT03989414 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) (Up to approximately 5 years): Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09). (met)
Result source: NCT05552976
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ICP-490 | Mezigdomide |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT05552976 |
| OS, median | —Not reported | —Trial running · NCT05552976 |
| ORR | —Not reported | —Trial running · NCT05552976 |
| VGPR or better | —Not reported | —Trial running · NCT05552976 |
| MRD negativity | —Not reported | —Trial running · NCT05552976 |
PFS, median
- ICP-490
- —Not reported
- Mezigdomide
- —Trial running · NCT05552976
OS, median
- ICP-490
- —Not reported
- Mezigdomide
- —Trial running · NCT05552976
ORR
- ICP-490
- —Not reported
- Mezigdomide
- —Trial running · NCT05552976
VGPR or better
- ICP-490
- —Not reported
- Mezigdomide
- —Trial running · NCT05552976
MRD negativity
- ICP-490
- —Not reported
- Mezigdomide
- —Trial running · NCT05552976
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ICP-490: no structured comparison results are available for Multiple Myeloma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ICP-490's landscape · Mezigdomide's landscape